LivaNova (NASDAQ:LIVN) Upgraded to “Strong-Buy” by Baird R W

Baird R W upgraded shares of LivaNova (NASDAQ:LIVN) from a hold rating to a strong-buy rating in a report published on Tuesday morning, Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Robert W. Baird raised LivaNova from a neutral rating to an outperform rating and increased their price target for the company from $55.00 to $66.00 in a research report on Tuesday. Stifel Nicolaus raised their target price on shares of LivaNova from $70.00 to $72.00 and gave the company a buy rating in a report on Thursday, July 25th. Finally, Needham & Company LLC lifted their price target on shares of LivaNova from $72.00 to $75.00 and gave the stock a buy rating in a research note on Wednesday, July 31st. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, LivaNova has a consensus rating of Buy and a consensus price target of $70.80.

LivaNova Price Performance

Shares of LIVN opened at $51.00 on Tuesday. The company has a market cap of $2.76 billion, a P/E ratio of -85.00 and a beta of 1.00. LivaNova has a fifty-two week low of $42.75 and a fifty-two week high of $64.47. The company has a quick ratio of 2.94, a current ratio of 3.45 and a debt-to-equity ratio of 0.49. The firm’s 50 day moving average price is $48.86 and its 200 day moving average price is $53.44.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.66 by $0.15. The business had revenue of $318.60 million during the quarter, compared to the consensus estimate of $305.05 million. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. On average, research analysts forecast that LivaNova will post 2.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LivaNova

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Primecap Management Co. CA boosted its holdings in LivaNova by 0.7% in the second quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company’s stock valued at $327,889,000 after purchasing an additional 44,049 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of LivaNova by 3.5% in the 1st quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company’s stock valued at $102,537,000 after buying an additional 62,480 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of LivaNova by 204.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company’s stock valued at $70,479,000 after buying an additional 863,157 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of LivaNova by 6.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,241,985 shares of the company’s stock valued at $64,262,000 after buying an additional 74,067 shares during the last quarter. Finally, Greenlight Capital Inc. raised its stake in LivaNova by 3.5% during the 4th quarter. Greenlight Capital Inc. now owns 1,229,316 shares of the company’s stock worth $63,605,000 after acquiring an additional 42,040 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.